SLE: Variability in Racial Disparities in Pregnancy Outcomes

Save

Significant disparities exist in pregnancy outcomes in women with systemic lupus erythematosus (SLE), with previous cohorts identifying Black women as having a higher risk of maternal mortality compared to White women with SLE.

Why treatment of pre-RA isn't ready for prime time

Save

The ACR Great Debate was on "To treat or not to treat in pre-RA?". What is the clinician to do?

ACR 2022 Appraisal, Praise & Critique (11.18.2022)

Save

It was great to be back at an ACR annual meeting, this one in Philadelphia - Philly was great. A walking town, rich in culture, history and good places to meet and mingle. 

I loved the city, but not the convention center (not easy to navigate). 

ACR Best Abstracts - Day 3

Save

The last day was jammed with important reports and research including the late breaking abstracts. 

ACR Best Abstracts - Day 2

Save

Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.

Here are the RheumNow faculty selections for #ACRbest abstracts today:

Does Evusheld shield people living with rheumatic diseases?

Save

While COVID vaccination and subsequent booster remain the cornerstone, pre-exposure prophylaxis such as Evusheld (tixagevimab and cilgavimab) has been approved by FDA in December 2021 and EMA in March 2022 for people immunocompromised either due to a medical condition or receiving treatment with immunosuppressants and may not mount an adequate immune response to COVID vaccination. How does this therapy fare in RMD patients?

SLE, Sex and STDs

Save

Once in a while, I find an abstract at the ACR meeting that can potentially save lives and be implemented in practice now.  

In Abstract #0939, Dr. J Patricia Dhar and colleagues shared data from a pilot study examining a new method to monitor cervical health in African American Women with Systemic Lupus Erythematosus (SLE) using a self-sampling brush to assess cervical cytology and human papilloma virus infection.

TNFi cycling in axSpA: Results from CorEVITAS Registy study

Save

Data presented at ACR22 shows that cycling through TNFi in axSpA patients with primary lack of efficacy with first line TNFi has limited additional benefit in controlling disease. 

Where are we with treating Pre-Rheumatoid Arthritis?

Save

The ability to prevent RA in individuals at risk is a holy grail in rheumatology. There is a long history dating back to the PROMPT trial of methotrexate and PRAIRIE trial of rituximab. Both otrials showed an effect, but it seemed more likely to be a delaying of RA than prevention or modulation. Framing it another way, there were better outcomes in pre-RA because we were actually treating RA as it emerged with a proven effective treatment. It is in this setting that three trials of ongoing studies in RA preventative therapy are presented at ACR.

Are MDA criteria created equal in PsA?

Save

Minimal Disease Activity criteria are used to evaluate PsA disease activity and response to treatment. Given that a patient only has to meet 5 of the 7 criteria, should the individual components be weighted equally? 

Are we really treating Psoriatic disease if we only address active disease domains and T2T?

Save

It’s widely accepted that Psoriatic disease has multi-system, multi-domain potential that can lead to life altering complications if left untreated or undertreated. Rheumatologists have shifted the way we discuss treatment options and disease state expectations with patients. Two #ACR22 abstracts stood out to me regarding the Psoriatic disease patient experience and will, ultimately, add to what I do in clinic. 

Updates on Reproductive Health in Women with SLE

Save

Is patient-administered cervical cancer screening an option for women with SLE? Should I prescribe estrogen containing contraceptives to SLE women with APL antibodies? What complications should I be aware of in pregnant women with SLE? Here are three abstracts that provide insight.

Proposed Cancer Screening for Inflammatory Myositis Patients

Save

Today's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer.  Abstract 0002 by Oldroyd et al, entitled "Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myopathy" took on this thorny practice issue. 

Survival and Mortality in RA: time to move away from “one-size fits all”?

Save

Patients with RA are known to have a higher mortality risk than the general population.

Anifrolumab shows long-term promise in patients with lupus

Save

Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease.

Long COVID and Rheumatic Disease

Save

The COVID-19 pandemic has had a significant impact worldwide particularly among those who are immunocompromised. Numerous studies have highlighted the increased risk of acute SARS-CoV-2 infection among patients with rheumatic diseases (RD).

Creaky Joints Presentations at ACR Convergence 2022

Save

The patient advocacy organization CreakyJoints will present 13 scientific posters at this year's ACR Convergence 2022 and 8 posters as part of the patient perspectives track. Below is a sampling of these scientific posters.